DUBAI: The Ministry of Health & Prevention, United Arab Emirates, had cleared the emergency use of Sinopharm's protein-based COVID-19 vaccine, which would be provided to the public as a booster dosage beginning January 2022.
The approval came after strict scrutiny and examination of data from the United Arab Emirates research.
Individuals who had previously received two doses of Sinopharm CNBG's inactivated vaccine were included in the trial. The rate of seroconversion (efficacy) in producing neutralising antibodies was up to 100%. None of the subjects reported any side effects.
According to the government, the vaccine exhibited improved immunological potential against SARS-CoV-2 variations and had a high safety rate, allowing for quick production, storage, and distribution. In addition, volunteers in the UAE-based study revealed an immunological response to newer viral strains.